TKG Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TKG Therapeutics, Inc. - overview
Established
2022
Location
Tokyo, -, Japan
Primary Industry
Biotechnology
About
Founded in 2022 and based in Tokyo, Japan, TKG Therapeutics, Inc. is a research and developer of cancer immunity drugs. As of 2024, the company is headed by its CEO Masaaki Matsui. In January 2024, the firm raised JPY 150 million in Seed funding from investors Real Tech Japan and MITSUBISHI GAS CHEMICAL COMPANY, INC.
The company offers nucleic acid-derived cancer medicine that will allow natural immunity to fight the disease. To create nucleic acid aggregates that target disease cells and are identified as foreign substances, the company pharmaceuticals employ miRNA, which is specifically overexpressed in cancer cells, as a biomarker. This triggers innate immunity and ultimately results in cancer cell death. The company plans to use the January 2024 funding to develop its pharmaceutical formula, perform pre-clinical trials, and develop new machines for nucleic acid synthesis.
Current Investors
UntroD Capital, MITSUBISHI GAS CHEMICAL COMPANY, INC.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.tkg-na.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.